The company utilizes third-party vendors, suppliers, and contractors for the majority of its research, development, manufacturing, and clinical activities, maintaining limited internal manufacturing capacity for short-duration preclinical studies. All antibody drug candidates, including XmAb819, XmAb541, XmAb808, plamotamab, XmAb942, XmAb657, and XmAb412, are produced by third-party manufacturers compliant with current Good Manufacturing Practices (cGMP). Additional contract manufacturers manage fill, finish, labeling, packaging, and distribution processes. The company holds no long-term manufacturing commitments and intends to continue outsourcing clinical and commercial supply as well as process development.
Key agreements include a master services agreement with Alimentiv Inc. for contract research organization (CRO) services supporting the XmAb942 clinical program; a master services agreement with Kapadi (formerly OncoBay Clinical, Inc.) for CRO services supporting the XmAb541 clinical program; a non-exclusive license agreement with BIO-TECHNE for a recombinant monoclonal antibody used in the XmAb541 program; a master services agreement with WuXi Biologics (Hong Kong) Limited for manufacturing, analytical, and development services related to the XmAb808, XmAb657, XmAb942, and XmAb412 programs; and a master services agreement with Vetter Pharma International GmbH.
Xencor Inc's Comment on Supply Chain
The company utilizes third-party vendors, suppliers, and contractors for the majority of its research, development, manufacturing, and clinical activities, maintaining limited internal manufacturing capacity for short-duration preclinical studies. All antibody drug candidates, including XmAb819, XmAb541, XmAb808, plamotamab, XmAb942, XmAb657, and XmAb412, are produced by third-party manufacturers compliant with current Good Manufacturing Practices (cGMP). Additional contract manufacturers manage fill, finish, labeling, packaging, and distribution processes. The company holds no long-term manufacturing commitments and intends to continue outsourcing clinical and commercial supply as well as process development.
Key agreements include a master services agreement with Alimentiv Inc. for contract research organization (CRO) services supporting the XmAb942 clinical program; a master services agreement with Kapadi (formerly OncoBay Clinical, Inc.) for CRO services supporting the XmAb541 clinical program; a non-exclusive license agreement with BIO-TECHNE for a recombinant monoclonal antibody used in the XmAb541 program; a master services agreement with WuXi Biologics (Hong Kong) Limited for manufacturing, analytical, and development services related to the XmAb808, XmAb657, XmAb942, and XmAb412 programs; and a master services agreement with Vetter Pharma International GmbH.
Sources:
Xencor Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Xencor Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
